Roflumilast
Roflumilast 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Diffuse Large B-cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
13 项
全球在招研究
3 项
已进入 III/IV 期
3 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- The University of Texas Health Science Center at San Antonio
- Derm Texas, PLLC
- Ahmed Ibrahim
- University of Arizona
- Integrative Skin Science and Research
- Horus University
- Tanta University
- Nora Mohamed Abdelrazik
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Egypt、德国
正在招募患者的 Roflumilast 研究
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
II 期招募中美国NCT07105254A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults
II 期招募中EgyptNCT07233291Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
早期 I 期招募中美国NCT06643221Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
IV 期招募中美国NCT07560618Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis
II 期招募中EgyptNCT07632846Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis
II 期招募中EgyptNCT07566351Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients
III 期招募中EgyptNCT06860958Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
I 期招募中美国NCT06977711Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study
II 期招募中EgyptNCT07297602The Safety and Efficacy of Roflumilast Foam in HS
II 期招募中美国NCT07263230Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
II 期招募中美国NCT07689188An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis
IV 期招募中美国NCT07725822Effects of Pulmonary Diseases and Their Treatment on Cardiac Function
不适用招募中德国NCT05042219
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。